Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
暂无分享,去创建一个
Yan Li | Yonghua Wang | Yan Li | Ling Yang | Yan-hong Li | Sheng-Li Yang | Ling Yang | Sheng-Li Yang | Yong-Hua Wang | Yan-Hong Li
[1] U. Christians,et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[2] B. Bruguerolle,et al. Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[3] R. Branch,et al. Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[4] Keli Han,et al. Structural determinants of steroids for cytochrome P450 3A4-mediated metabolism , 2004 .
[5] David A Winkler,et al. Modelling blood-brain barrier partitioning using Bayesian neural nets. , 2004, Journal of molecular graphics & modelling.
[6] Matej Oresic,et al. Integrative biological analysis of the APOE*3-leiden transgenic mouse. , 2004, Omics : a journal of integrative biology.
[7] M. Odomi,et al. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation , 1998, European Journal of Clinical Pharmacology.
[8] F. Gonzalez,et al. Cytochrome P-450 3A4 (nifedipine oxidase) is responsible for the C-oxidative metabolism of 1-nitropyrene in human liver microsomal samples. , 1992, Cancer research.
[9] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[10] S. Wrighton,et al. In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[11] L. Benet,et al. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[12] K. Wikvall,et al. 6α-Hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes , 1999 .
[13] B. K. Park,et al. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. , 1996, The Journal of pharmacology and experimental therapeutics.
[14] J. Miners,et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.
[15] K. Chiba,et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. , 1998, The Journal of pharmacology and experimental therapeutics.
[16] Ortiz de Montellano,et al. Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .
[17] D. Greenblatt,et al. Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N‐Desmethyladinazolam in Man , 1998, The Journal of pharmacy and pharmacology.
[18] David J. C. MacKay,et al. Bayesian Interpolation , 1992, Neural Computation.
[19] D. Greenblatt,et al. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[20] D. Greenblatt,et al. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. , 2001, The Journal of pharmacology and experimental therapeutics.
[21] C. Miranda,et al. Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid senecionine in human liver. , 1991, Carcinogenesis.
[22] M. Clay,et al. In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[23] J. W. Allis,et al. Kinetics of bromodichloromethane metabolism by cytochrome P450 isoenzymes in human liver microsomes. , 2002, Chemico-biological interactions.
[24] H. Yamazaki,et al. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[25] T Ishizaki,et al. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. , 1997, The Journal of pharmacology and experimental therapeutics.
[26] R. Obach. Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[27] William D. Penny,et al. An empirical evaluation of Bayesian sampling with hybrid Monte Carlo for training neural network classifiers , 1999, Neural Networks.
[28] L. Wienkers,et al. Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[29] D. Greenblatt,et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects , 1999, Biological Psychiatry.
[30] A. D. Rodrigues,et al. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[31] L. Hall,et al. Molecular Structure Description: The Electrotopological State , 1999 .
[32] H. Yamazaki,et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. , 1994, Biochemical pharmacology.
[33] L. Benet,et al. Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[34] F. Burden,et al. Robust QSAR models using Bayesian regularized neural networks. , 1999, Journal of medicinal chemistry.
[35] Jarmo Huuskonen. QSAR Modeling with the Electrotopological State: TIBO Derivatives , 2001, J. Chem. Inf. Comput. Sci..
[36] D. Flockhart,et al. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. , 1998, The Journal of pharmacology and experimental therapeutics.
[37] David J. C. MacKay,et al. A Practical Bayesian Framework for Backpropagation Networks , 1992, Neural Computation.
[38] M. Murray,et al. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.
[39] Lemont B. Kier,et al. Modeling Blood-Brain Barrier Partitioning Using the Electrotopological State , 2002, J. Chem. Inf. Comput. Sci..
[40] Geoffrey E. Hinton,et al. Bayesian Learning for Neural Networks , 1995 .
[41] Ryo Shoji. The Potential Performance of Artificial Neural Networks in QSTRs for Predicting Ecotoxicity of Environmental Pollutants , 2005 .
[42] J. Lasker,et al. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[43] P. Maurel,et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[44] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[45] T. Koudriakova,et al. Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents , 1997, Clinical pharmacology and therapeutics.
[46] M. Eichelbaum,et al. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.
[47] G. de Sousa,et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.
[48] A. Kalgutkar,et al. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[49] Christopher M. Bishop,et al. Neural networks for pattern recognition , 1995 .
[50] B H Arison,et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[51] H. Yamazaki,et al. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[52] H. Yamazaki,et al. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[53] A. D. Rodrigues,et al. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[54] P. Souček,et al. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. , 1997, Biochemical pharmacology.
[55] A. D. Rodrigues,et al. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[56] O. Olesen,et al. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[57] I Skånberg,et al. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. , 2009, Acta pharmacologica et toxicologica.
[58] T. Walle,et al. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. , 1994, The Journal of pharmacology and experimental therapeutics.
[59] D. Greenblatt,et al. Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. , 1996, Pharmacology.
[60] M. Hino,et al. Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[61] L. Bertilsson,et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. , 2003, British journal of clinical pharmacology.
[62] S K Balani,et al. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[63] J. Halpert,et al. The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4. , 2000, Archives of biochemistry and biophysics.
[64] S. M. Abel,et al. Cortisol metabolism in vitro—III. Inhibition of microsomal 6β—hydroxylase and cytosolic 4-ene-reductase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[65] L. Benet,et al. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. , 1996, Biochemical pharmacology.
[66] P. Beaune,et al. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.
[67] A. Y. Lu,et al. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[68] D. Greenblatt,et al. O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants , 1999, Neuropsychopharmacology.
[69] X. J. Zhou,et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. , 1993, Cancer research.
[70] K. Chiba,et al. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. , 1996, The Journal of pharmacology and experimental therapeutics.